An integration of complementary strategies for gene expression analysis to reveal novel therapeutic opportunities for breast cancer

IntroductionPerhaps the chief trial in developing bounteous effective therapeutic strategies for the treatment of breast cancer patients is confronting the heterogeneity of the disease, recognizing that breast cancer is not one disease nevertheless multiple disorders with distinct underlying mechanisms. Gene-expression profiling studies compass been used to dissect this complexity, and our previous studies identified a series of intrinsic subtypes of breast cancer that define many populations of patients with appreciation to survival. Additional assignment has also used signatures of oncogenic pathway deregulation to dissect breast cancer heterogeneity as able-bodied as to suggest therapeutic opportunities linked to course of action activation. Methods: We used genomic analyzes to distinguish relations between breast cancer subtypes, pathway deregulation, and drug sensitivity. For these studies, we avail three independent breast cancer gene-expression material sets to measure an individual tumor phenotype. Correlation between system status and subtype are examined and linked to predictions for response to conventional chemotherapies. Results: We explain patterns of means activation characteristic of each molecular breast cancer subtype, including within the more aggressive subtypes in which novel therapeutic opportunities are critically needed. Whereas some oncogenic pathways get high correlations to breast cancer subtype (RAS, CTNNB1, p53, HER1), others obtain colossal variability of labor within a specific subtype (MYC, E2F3, SRC), reflecting biology independent of average clinical factors. Additionally, we combined these analyses with predictions of sensitivity to commonly used cytotoxic chemotherapies to accommodate fresh opportunities for therapeutics specific to the intrinsic subtype that might be higher quality aligned with the characteristics of the individual patient. Conclusions: Genomic analyses can be used to dissect the heterogeneity of breast cancer. We use an integrated analysis of breast cancer that combines independent methods of genomic analyses to highlight the complexity of signaling pathways underlying different breast cancer phenotypes and to distinguish optimal therapeutic opportunities.

Keywords: